{"id":38601,"date":"2023-08-30T13:02:44","date_gmt":"2023-08-30T13:02:44","guid":{"rendered":"https:\/\/\u200bnew.iter.es\/pharma-can\/"},"modified":"2025-06-13T08:56:46","modified_gmt":"2025-06-13T08:56:46","slug":"pharma-can","status":"publish","type":"post","link":"https:\/\/www.iter.es\/en\/pharma-can\/","title":{"rendered":"PHARMA-CAN"},"content":{"rendered":"
\n
\n
\n
\n
\n

Pharmacogenomic variant analysis using next-generation sequencing data<\/h3>\n

Data<\/h3>\n

Acronym<\/strong>: PHARMA-CAN
\nReference<\/b>: ProID2021010073
\nPartners<\/strong>: Instituto Tecnol\u00f3gico y de Energ\u00edas Renovables (ITER) and Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias (FIISC)
\nDuration<\/strong>: 01 March 2021 – 04 April 2023
\nBudget<\/strong>: 38,990.15\u20ac
\nCo-financing<\/strong>: FEDER\/Government of the Canary Island<\/p>\n

Call for Subsidies for the implementation of R&D projects by research organisations and companies in the priority areas of the Canary Islands Smart Specialisation Strategy (RIS-3). Co-financed by the Canary Islands FEDER Operational Programme 2014-2020. <\/p>\n

\"\"<\/p>\n

\n
\n
\n

Project overview<\/h3>\n

El objetivo general del proyecto PHARMA-CAN es contribuir a la mejora en la prescripci\u00f3n de f\u00e1rmacos considerando los polimorfismos farmacogen\u00e9ticos presentes en la poblaci\u00f3n canaria mediante el uso de la secuenciaci\u00f3n del exoma completo, con el fin de reducir la toxicidad y los efectos adversos del f\u00e1rmaco.<\/p>\n

For this purpose, the variation in the main genes and variants of interest collected in public pharmacogenetic databases will be studied in order to determine the variation, as well as the frequency of the existing variants in the population under study and to modify, if necessary, the design of exome capture to allow simultaneous study with genetic diagnosis.<\/p>\n

PHARMA-CAN develops its activities in coordination with the consortium formed by the Canary Islands Health Research Institute Foundation (FIISC) and ITER. On the one hand, ITER is responsible for the development of the genomics protocols and the deployment and maintenance of all the elements of the technological tool. On the other hand, FIISC is responsible for providing its knowledge in the field of the application of genomics in health and for developing the analyses necessary to carry out the comparisons, refining its own database, as well as the clinical perspective of the project. <\/p>\n

The results of this project will allow the automated extraction of variants of pharmacogenetic interest from the exome sequencing data, with which we will be able to contribute to the improvement of drug prescription, enhancing the focus of Personalised Medicine in the general population.<\/p>\n

In the PHARMA-CAN project, whole exome sequencing will be performed using ITER’s next-generation massive DNA sequencing platforms and supercomputing infrastructures.<\/p>\n<\/div>\n

Links of interest:<\/strong><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n
<\/div>\n
Genomics<\/a><\/div>\n
<\/div>\n
Grant<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Pharmacogenomic variant analysis using next-generation sequencing data Data Acronym: PHARMA-CAN Reference: ProID2021010073 Partners: Instituto Tecnol\u00f3gico y de Energ\u00edas Renovables (ITER) and Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias (FIISC) Duration: 01 March 2021 – 04 April 2023 Budget: 38,990.15\u20ac Co-financing: FEDER\/Government of the Canary Island Call for Subsidies for the implementation of R&D projects<\/p>\n","protected":false},"author":1,"featured_media":36803,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[210,74,209],"tags":[212],"class_list":{"0":"post-38601","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-activities","8":"category-genomics","9":"category-projects","10":"tag-genomics-en"},"_links":{"self":[{"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/posts\/38601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/comments?post=38601"}],"version-history":[{"count":1,"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/posts\/38601\/revisions"}],"predecessor-version":[{"id":39393,"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/posts\/38601\/revisions\/39393"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/media\/36803"}],"wp:attachment":[{"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/media?parent=38601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/categories?post=38601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iter.es\/en\/wp-json\/wp\/v2\/tags?post=38601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}